These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

376 related articles for article (PubMed ID: 33684397)

  • 21. Identification of promising antiviral drug candidates against non-structural protein 15 (NSP15) from SARS-CoV-2: an
    Khan RJ; Jha RK; Singh E; Jain M; Amera GM; Singh RP; Muthukumaran J; Singh AK
    J Biomol Struct Dyn; 2022 Jan; 40(1):438-448. PubMed ID: 32885740
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Repurposing of FDA-approved antivirals, antibiotics, anthelmintics, antioxidants, and cell protectives against SARS-CoV-2 papain-like protease.
    Kandeel M; Abdelrahman AHM; Oh-Hashi K; Ibrahim A; Venugopala KN; Morsy MA; Ibrahim MAA
    J Biomol Struct Dyn; 2021 Sep; 39(14):5129-5136. PubMed ID: 32597315
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Repurposing simeprevir, calpain inhibitor IV and a cathepsin F inhibitor against SARS-CoV-2 and insights into their interactions with M
    J A; Francis D; C S S; K G A; C S; Variyar EJ
    J Biomol Struct Dyn; 2022 Jan; 40(1):325-336. PubMed ID: 32873185
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Drug Repurposing to Identify Nilotinib as a Potential SARS-CoV-2 Main Protease Inhibitor: Insights from a Computational and
    Banerjee S; Yadav S; Banerjee S; Fakayode SO; Parvathareddy J; Reichard W; Surendranathan S; Mahmud F; Whatcott R; Thammathong J; Meibohm B; Miller DD; Jonsson CB; Dubey KD
    J Chem Inf Model; 2021 Nov; 61(11):5469-5483. PubMed ID: 34666487
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In silico drug repurposing for coronavirus (COVID-19): screening known HCV drugs against the SARS-CoV-2 spike protein bound to angiotensin-converting enzyme 2 (ACE2) (6M0J).
    Kalamatianos KG
    Mol Divers; 2023 Jun; 27(3):1087-1099. PubMed ID: 35739375
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Multi-targeting approach for nsp3, nsp9, nsp12 and nsp15 proteins of SARS-CoV-2 by Diosmin as illustrated by molecular docking and molecular dynamics simulation methodologies.
    Kumar S; Sharma PP; Upadhyay C; Kempaiah P; Rathi B; Poonam
    Methods; 2021 Nov; 195():44-56. PubMed ID: 33639316
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Fast Identification of Possible Drug Treatment of Coronavirus Disease-19 (COVID-19) through Computational Drug Repurposing Study.
    Wang J
    J Chem Inf Model; 2020 Jun; 60(6):3277-3286. PubMed ID: 32315171
    [TBL] [Abstract][Full Text] [Related]  

  • 28.
    Maurya AK; Mishra N
    J Biomol Struct Dyn; 2021 Nov; 39(18):7306-7321. PubMed ID: 32835632
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Repurposing drug molecule against SARS-Cov-2 (COVID-19) through molecular docking and dynamics: a quick approach to pick FDA-approved drugs.
    Farhat N; Khan AU
    J Mol Model; 2021 Oct; 27(11):312. PubMed ID: 34601658
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Repurposing of US-FDA approved drugs against SARS-CoV-2 main protease (M
    Khan AM; Atia-Tul-Wahab ; Farooq S; Ullah A; Choudhary MI
    Int J Biol Macromol; 2023 Apr; 234():123540. PubMed ID: 36740128
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Computational guided drug repurposing for targeting 2'-O-ribose methyltransferase of SARS-CoV-2.
    Sharma K; Morla S; Goyal A; Kumar S
    Life Sci; 2020 Oct; 259():118169. PubMed ID: 32738360
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Anti-HCV and anti-malaria agent, potential candidates to repurpose for coronavirus infection: Virtual screening, molecular docking, and molecular dynamics simulation study.
    Hosseini FS; Amanlou M
    Life Sci; 2020 Oct; 258():118205. PubMed ID: 32777300
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Raltegravir, Indinavir, Tipranavir, Dolutegravir, and Etravirine against main protease and RNA-dependent RNA polymerase of SARS-CoV-2: A molecular docking and drug repurposing approach.
    Indu P; Rameshkumar MR; Arunagirinathan N; Al-Dhabi NA; Valan Arasu M; Ignacimuthu S
    J Infect Public Health; 2020 Dec; 13(12):1856-1861. PubMed ID: 33168456
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Drug repurposing for identification of potential spike inhibitors for SARS-CoV-2 using molecular docking and molecular dynamics simulations.
    Lazniewski M; Dermawan D; Hidayat S; Muchtaridi M; Dawson WK; Plewczynski D
    Methods; 2022 Jul; 203():498-510. PubMed ID: 35167916
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Possibility of HIV-1 protease inhibitors-clinical trial drugs as repurposed drugs for SARS-CoV-2 main protease: a molecular docking, molecular dynamics and binding free energy simulation study.
    Ancy I; Sivanandam M; Kumaradhas P
    J Biomol Struct Dyn; 2021 Sep; 39(15):5368-5375. PubMed ID: 32627689
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Virtual screening, molecular dynamics and structure-activity relationship studies to identify potent approved drugs for Covid-19 treatment.
    Rahman MM; Saha T; Islam KJ; Suman RH; Biswas S; Rahat EU; Hossen MR; Islam R; Hossain MN; Mamun AA; Khan M; Ali MA; Halim MA
    J Biomol Struct Dyn; 2021 Oct; 39(16):6231-6241. PubMed ID: 32692306
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Structure-based drug repurposing for targeting Nsp9 replicase and spike proteins of severe acute respiratory syndrome coronavirus 2.
    Chandel V; Sharma PP; Raj S; Choudhari R; Rathi B; Kumar D
    J Biomol Struct Dyn; 2022 Jan; 40(1):249-262. PubMed ID: 32838660
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of apigenin-based biflavonoid derivatives as potential therapeutic agents against viral protease (3CLpro) of SARS-CoV-2 via molecular docking, molecular dynamics and quantum mechanics studies.
    Abdizadeh R; Hadizadeh F; Abdizadeh T
    J Biomol Struct Dyn; 2023; 41(13):5915-5945. PubMed ID: 35848354
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Identification of potential inhibitors against SARS-CoV-2 by targeting proteins responsible for envelope formation and virion assembly using docking based virtual screening, and pharmacokinetics approaches.
    Bhowmik D; Nandi R; Jagadeesan R; Kumar N; Prakash A; Kumar D
    Infect Genet Evol; 2020 Oct; 84():104451. PubMed ID: 32640381
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Drug repurposing against SARS-CoV-2 receptor binding domain using ensemble-based virtual screening and molecular dynamics simulations.
    Kumar V; Liu H; Wu C
    Comput Biol Med; 2021 Aug; 135():104634. PubMed ID: 34256255
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.